Por favor, use este identificador para citar o enlazar este ítem:
https://www.arca.fiocruz.br/handle/icict/11442
Tipo
ArtículoDerechos de autor
Acceso restringido
Colecciones
Metadatos
Mostrar el registro completo del ítem
TARGETING SCHISTOSOME HISTONE MODIFYING ENZYMES FOR DRUG DEVELOPMENT
histone modifying enzyme
histone deacetylase
inhibitor
drug target
praziquantel
apoptosis
schistosome genes
SEtTReND
SmHDAC8
Autor
Afiliación
Institut Pasteur de Lille. Lille, France/Universite Lille Nord de France. Lille, France
Institut Pasteur de Lille. Lille, France/Universite Lille Nord de France. Lille, France
Institut Pasteur de Lille. Lille, France/Universite Lille Nord de France. Lille, France
Fundação Oswaldo Cruz. Centro de Pesquisas René Rachou. Centro de Excelencia em Bioinformatica, Genomica e Grupo de Biologia Computacional. Belo Horizonte, MG, Brazil/Instituto Nacional para Ciencia e Tecnologia em Doenças Tropicais
Fundação Oswaldo Cruz. Centro de Pesquisas René Rachou. Centro de Excelencia em Bioinformatica, Genomica e Grupo de Biologia Computacional. Belo Horizonte, MG, Brazil/Instituto Nacional para Ciencia e Tecnologia em Doenças Tropicais
Institut Pasteur de Lille. Lille, France/Universite Lille Nord de France. Lille, France
Institut Pasteur de Lille. Lille, France/Universite Lille Nord de France. Lille, France
Fundação Oswaldo Cruz. Centro de Pesquisas René Rachou. Centro de Excelencia em Bioinformatica, Genomica e Grupo de Biologia Computacional. Belo Horizonte, MG, Brazil/Instituto Nacional para Ciencia e Tecnologia em Doenças Tropicais
Fundação Oswaldo Cruz. Centro de Pesquisas René Rachou. Centro de Excelencia em Bioinformatica, Genomica e Grupo de Biologia Computacional. Belo Horizonte, MG, Brazil/Instituto Nacional para Ciencia e Tecnologia em Doenças Tropicais
Resumen en ingles
The histone modifying enzymes (HME) represent particularly promising targets for the development of alternatives to praziquantel, the only currently available drug to combat schistosomiasis. The inhibition of these enzymes frequently arrests the cell cycle or induces apoptosis in cancer cells, but not in normal cells and numerous HME inhibitors are under investigation as potential anticancer agents. The recent resolution of the genome sequences of Schistosoma mansoni and Schistosoma japonicum has allowed us to identify all the schistosome genes encoding histone acetyltransferases, deacetylases, methyltransferases and demethylases. We have chosen a strategy using phylogenetic screening with inhibitors of HME classes, screening of individual HME targets by both high-throughput and reasoned (in silico docking using resolved crystal structures) approaches in a project funded by the European Community, named SEtTReND (Schistosome Epigenetics: Targets, Regulation, New Drugs). The initial focus is on the class I histone deacetylase (HDAC) 8 since the comparison of the catalytic site of the schistosome and human enzymes shows crucial differences, rendering possible the development of inhibitors specific for SmHDAC8. However, phenotypic screening shows that inhibitors of all HME classes tested were able to induce apoptosis and death in parasites in vitro, indicating that other enzymes may prove to be viable targets.
Palabras clave en ingles
Schistosoma mansonihistone modifying enzyme
histone deacetylase
inhibitor
drug target
praziquantel
apoptosis
schistosome genes
SEtTReND
SmHDAC8
Compartir